3-Methylcholanthrene-induced transforming growth factor-β-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy

Cancer Science

Volumn 101, Issue 4, 2010, Pages 855-861

  Chamoto, Kenji ^a   Wakita, Daiko ^b   Ohkuri, Takayuki ^a   Uchinami, Yusuke ^a   Matsushima, Kouji ^c   Kitamura, Hidemitsu ^a   Nishimura, Takashi ^a,b  

^a Divisions of Immunoregulation ^*  (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; BASILIXIMAB; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CARCINOMA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SARCOMA; SQUAMOUS CELL CARCINOMA; T CELL DEPLETION; TUMOR ESCAPE; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; FEMALE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE DEPLETION; METHYLCHOLANTHRENE; MICE; MICE, INBRED BALB C; SARCOMA; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 77957279151     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01469.x     Document Type: Article

References (40)

1. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 617-27.
2. Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7: 880-7.
3. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
4. Ikeda H, Chamoto K, Tsuji T et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004; 95: 697-703. Review.
5. Johansson M, Denardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Rev 2008; 222: 145-54. Review.
6. Stewart CA, Trinchieri G. Reinforcing suppression using regulators: a new link between STAT3, IL-23, and Tregs in tumor immunosuppression. Cancer Cell 2009; 15: 81-3.
7. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009; 183: 937-44.
8. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-8. Review.
9. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 17: 12293-7.
10. Ohta A, Gorelik E, Prasad SJ et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006; 103: 13132-7.
11. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58: 1-14. Review
12. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
13. Wakita D, Chamoto K, Ohkuri T et al. IFN-γ-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 2009; 30: 1408-15.
14. Grauer OM, Sutmuller RP, van Maren W et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 2008; 122: 1794-802.
15. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59: 3128-33.
16. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-8.
17. Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-5.
18. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135-42.
19. + T cells. J Immunol 2004; 173: 6526-31.
20. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-86.
21. + T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172: 5149-53.
22. + regulatory T cell proliferation. J Exp Med 2005; 202: 919-29.
23. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2: 46-53.
24. Yamaguchi T, Hirota K, Nagahama K et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007; 27: 145-59.
25. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. Triggering of OX40 (CD134) on CD4+ CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005; 105: 2845-51.
26. + regulatory T cell function. Science 2005; 309: 1380-4.
27. Liu A, Hu P, Khawli LA, Epstein AL. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res 2005; 11: 8492-502.
28. + regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007; 98: 416-23.
29. + regulatory T cells in normal and tumor-bearing mice. Int Immunopharmacol 2004; 4: 1785-93.
30. Takiuchi H, Tada T, Li XF et al. Particular types of tumor cells have the capacity to convert transforming growth factor beta from a latent to an active form. Cancer Res 1992; 52: 5641-6.
31. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
32. Simpson A, Caballero O, Jungbluth A, Chen Y, Old L. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
33. Chamoto K, Wakita D, Narita Y et al. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res 2006; 66: 1809-17.
34. Wakita D, Chamoto K, Zhang Y et al. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int Immunol 2006; 18: 425-34.
35. + regulatory T cells in wild-type hosts. Proc Natl Acad Sci USA 2005; 102: 9253-7.
36. Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006; 214: 229-38. Review.
37. Nishikawa H, Tsuji T, Jäger E et al. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 2008; 111: 1404-12.
38. Nishikawa H, Kato T, Tawara I et al. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med 2005; 201: 681-6.
39. Wang HY, Lee DA, Peng G et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004; 20: 107-18.
40. Zhang Y, Wakita D, Chamoto K et al. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol 2007; 19: 151-61.